🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Arm A Mylotarg plus DA Versus CPX-351

    Cardiff Oncology

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  2. Armodafinil 100 to 250 mg/day

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  3. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  4. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  5. Asenapine Sublingual Tablets 10 mg

    Amneal Pharma Europe Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  6. Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure, Aspirin® protect 300 mg Magensaftresistente Tablette Acetylsalicylsäure, Placebo of Aspirine 100 mg protect, placebo of aspirin 300 mg protect

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  7. Ataluren (PTC124®)

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  8. Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, prášek a rozpouštědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml prašek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p

    Lacuna Pharma Pty Ltd

    Acquired Antithrombin Deficiency (Heparin Resistance)

    phase 3 small molecule active

    1 trial

  9. Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  10. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  11. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  12. Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  13. Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  14. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  15. Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule

    Disc Medicine

    Parkinson's disease

    phase 3 small molecule active

    1 trial

  16. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  17. Atropine sulfate eye drops 0.01%

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myopia

    phase 3 small molecule active

    1 trial

  18. Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule

    Medice Arzneimittel Pütter GmbH & Co. KG

    Patients with ADHD (according to ICD-10 / DSM-5)

    phase 3 small molecule active

    1 trial

  19. Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet

    Lacuna Pharma Pty Ltd

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial

  20. Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet

    Lacuna Pharma Pty Ltd

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial

  21. Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  22. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  23. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  24. Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources